WO2006080086A1 - 中枢神経系の疲労回復又は疲労予防のための組成物 - Google Patents
中枢神経系の疲労回復又は疲労予防のための組成物 Download PDFInfo
- Publication number
- WO2006080086A1 WO2006080086A1 PCT/JP2005/001357 JP2005001357W WO2006080086A1 WO 2006080086 A1 WO2006080086 A1 WO 2006080086A1 JP 2005001357 W JP2005001357 W JP 2005001357W WO 2006080086 A1 WO2006080086 A1 WO 2006080086A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fatigue
- group
- nervous system
- central nervous
- amino acids
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 238000011084 recovery Methods 0.000 title claims abstract description 11
- 230000002265 prevention Effects 0.000 title claims abstract description 10
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 62
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 26
- 150000001413 amino acids Chemical class 0.000 claims abstract description 25
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 24
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229930182817 methionine Natural products 0.000 claims abstract description 20
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 15
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 14
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- -1 ferrolanine Chemical compound 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229940024606 amino acid Drugs 0.000 abstract description 23
- 210000004556 brain Anatomy 0.000 abstract description 19
- 229960004441 tyrosine Drugs 0.000 abstract description 16
- 235000013305 food Nutrition 0.000 abstract description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 229930182844 L-isoleucine Natural products 0.000 abstract description 2
- 235000019454 L-leucine Nutrition 0.000 abstract description 2
- 239000004395 L-leucine Substances 0.000 abstract description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 2
- 229920002472 Starch Polymers 0.000 abstract description 2
- 238000001802 infusion Methods 0.000 abstract description 2
- 229960000310 isoleucine Drugs 0.000 abstract description 2
- 239000008101 lactose Substances 0.000 abstract description 2
- 229960003136 leucine Drugs 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 239000008107 starch Substances 0.000 abstract description 2
- 235000019698 starch Nutrition 0.000 abstract description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 2
- 239000003651 drinking water Substances 0.000 abstract 1
- 235000020188 drinking water Nutrition 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 229960004295 valine Drugs 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 description 58
- 238000012360 testing method Methods 0.000 description 44
- 238000002474 experimental method Methods 0.000 description 22
- 229960004452 methionine Drugs 0.000 description 18
- 230000002996 emotional effect Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000282412 Homo Species 0.000 description 4
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 4
- 229930195722 L-methionine Natural products 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009661 fatigue test Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- JQIFJRXHLHKEAJ-UHFFFAOYSA-N 1-(2-chloroethyl)-4-[1-(2-chloroethyl)piperidin-4-yl]piperidine Chemical compound C1CN(CCCl)CCC1C1CCN(CCCl)CC1 JQIFJRXHLHKEAJ-UHFFFAOYSA-N 0.000 description 1
- NKBWMBRPILTCRD-UHFFFAOYSA-N 2-Methylheptanoic acid Chemical compound CCCCCC(C)C(O)=O NKBWMBRPILTCRD-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- Composition for recovery or prevention of fatigue of central nervous system Composition for recovery or prevention of fatigue of central nervous system
- the present invention relates to a composition for use in recovery or prevention of fatigue of the central nervous system, so-called brain fatigue.
- tributofan is a causative substance that induces brain fatigue
- administration of branched chain amino acid (BCAA) is effective in preventing or recovering brain fatigue.
- BCAA branched chain amino acid
- a patent application has been filed for an agent for preventing or recovering brain fatigue (including foods), which is an active ingredient (see Patent Document 1).
- BCH (2-aminobicyclo [2,2, l]
- Heptane-2-carboxylic add has been found to dramatically reduce brain fatigue, and a patent application has been filed for both of these agents (Patent Document 1).
- BCH can be used as an anticancer agent, but at the present time, its practical use has been difficult, and it has been difficult to put it to practical use.
- Non-Patent Document 1 L-phenylaniline, L-methionine, L-cysteine, L-leucine, and L-parin suppressed the uptake of triftophan.
- this report is about the placenta brush border organization.
- the present inventor further researched on a substance that has been widely used in the food field as a substitute for BCH.
- the above-mentioned amino acids which are essential amino acids of the human body like BCAA, are BCH.
- the present invention was found to contribute to the suppression of brain fatigue. It came to complete.
- Patent Document 1 International Publication WO02Z34257
- Non-patent literature l Yoshiki Kudo and C.A.R.Boyd "Journal of Physiology"
- Non-Patent Document 2 Miro Smriga, Makiko Kameishi et. Al. "Preference for a Solution of Branched Chain Amino Acids plus ulutamine and Arginine Correlates with Free Running Activity in Rats: Involvement of Serotonergic Dependent Process of Lateral Hypothalamus” Nutritional Neuroscience International Journal on Nutrition, Diet and Nervous system, 2001.11.19, p2002-Disclosure of the invention
- the present invention is to provide a composition that can be used as a food or a pharmaceutical that can be used to improve or suppress fatigue (brain fatigue) of the central nervous system, which is highly safe and highly effective.
- the composition for recovering or preventing fatigue of the central nervous system of the present invention comprises a group force selected from tyrosine, methionine, fulleranin, and glutamine, any one selected from one or more amino acids and a branched chain amino acid.
- a group force selected from tyrosine, methionine, fulleranin, and glutamine, any one selected from one or more amino acids and a branched chain amino acid.
- BCAA and tyrosine, and in addition to these, glutamine is used as an active ingredient
- the present invention relates to a group force consisting of tyrosine, methionine, fulleranin, and glutamine force for recovery of fatigue or prevention of fatigue of the central nervous system.
- the present invention there is no physical fatigue, for example, computer work or future activities. It is possible to improve or prevent brain fatigue caused by work in the space environment that will occur.
- the composition of the present invention can constitute only the power of amino acids, it can be said that its safety is almost probable, and its practicality is very high.
- the composition for recovery or prevention of fatigue uses a branched-chain amino acid (BCAA) and one or more amino acids selected from tyrosin, methionine, ferrolanine, and a group power that also has glutamine power. It is contained as a component.
- the fatigue of the central fatigue system is as described in the above-mentioned Patent Document 1. Unlike so-called fatigue caused by physical (muscle) fatigue, physical fatigue such as computer work and reading. It occurs in a state without accompanying.
- the fatigue prevention of the present invention is a case where it is applied mainly to humans prior to the case where fatigue of the central nervous system is scheduled in advance, and the recovery from fatigue is mainly performed after the fact when central nervous system fatigue has occurred in advance.
- composition for recovering or preventing fatigue of the central nervous system of the present invention can be applied regardless of the presence or absence of fatigue, and as a so-called specific health nutrition agent, the composition of central nervous system fatigue (brain fatigue) can be applied. New applications of recovery and prevention are planned.
- branched chain amino acid As the branched chain amino acid (BCAA), essential amino acids of the human body having a branched chain in the carbon chain, such as L parin, L bite isine, and L isoleucine are used. In addition, these amino acids can be used in their physiologically acceptable salts, such as hydrochlorides and various hydrates thereof. These branched chain amino acids can be used alone or as a mixture. When used as a mixture, the mixing ratio thereof is not particularly limited.
- amino acids used in combination with BCAA include L-tyrosine, L-methionine, L-felanalanin, and L-glutamine. At least one of these amino acids is used, but it is always used in combination with BCAA. Tyrosine is effective when one amino acid other than BCAA is used in combination.
- the amino acids used in combination with BCAA may be a combination of two amino acids or a combination of three or more amino acids. Two or more combinations are optional, but in particular L-tyrosine and L-glutamine, L-fetalan and L-methionine, L-fetalanin and L-methionine, L-chi A combination of mouth shin is effective. The amount ratio of each amino acid in combination can be determined as appropriate.
- BCAA is the main component, and the mass ratio is about 0.01-2, preferably about BCAA of 1 for BCAA. — 1 is enough. Further, even when a plurality of other amino acids are used, the total amount is sufficient within the above range. Of course, the amount of amino acids other than BCAA may be increased.
- composition of the present invention is in a form that can be applied to humans
- dosage and administration form are not particularly limited.
- injectable solutions or infusions that can be administered directly to the vascular system, lymphatic system, etc., and by adding appropriate excipients such as starch or lactose, solid forms such as tablets, condyles, powders, etc.
- excipients such as starch or lactose
- solid forms such as tablets, condyles, powders, etc.
- it can be provided in various drinking forms (for example, for food) such as so-called health drinks. It may also be provided in the form of a so-called food such as a biscuit or bowl.
- composition for recovery from fatigue or prevention includes, in addition to branched chain amino acids and other necessary amino acids, saccharides such as glucose sucrose, vitamin B groups such as vitamins B, B, and B. , Bi
- trybutophane is a causative agent of brain fatigue and has a negative effect on the combined effect, so tryptophan should not be included!
- a fatigue experiment was carried out in which a female albumin-free rat (Japan SLC) genetically deficient in plasma albumin was run on a treadmill. That is, prior to fatigue experiments, albumin-free rats raised under a light-dark cycle at room temperature 22 ° C, 7: 00-19: 00 (light hours), at a certain time between 13: 00-15: 00 I was trained 4 times a week for 30 minutes (20mZmin, 7% slope) for 4 weeks to get used to running on the treadmill. For all albumin-free rats after training In the same condition, a fatigue exercise was imposed on the treadmill, and the time to fatigue was measured. Fatigue was defined as the time when the rat was stuck or refused to run due to speed on the treadmill.
- Rats divided into 5 groups consisted of saline, BCAA, BCAA and ferrolanine, a combination of methionine (abbreviated as “BPM”), BCAA and ferrolanine, methionine, Each was treated with a combination of tribtophan (abbreviated “BPMT”).
- Saline was administered at a dose of 5 ml / kg, phenenolealanine at 125 mgZkg, methionine at 75 mg / kg, tryptophan at 85 mgZkg, and BCAA at 250 mgZkg, and given intraperitoneally one hour before the start of exercise.
- Various amino acids including BCAA were used after dissolving in physiological saline.
- BCAA used was a mixture of L-parin, L-sip Icin and L-isoleucine (weight ratio, 5: 3: 2). Incidentally, these dosages are determined in such a way that the effect will be manifested, and the actual dosages to humans can be appropriately changed depending on various factors. The results are shown in Table 1. In addition, various amino acids for food additives (manufactured by Nichi Kagaku Co., Ltd.) were used (the same applies to Example 2).
- Table 2 the multifaceted emotion scale item
- orange juice (“Natsuchiyan Orange” manufactured by Suntory Ltd .: orange, lemon juice, fructose, flavor, acidulant, vitamin C.
- Nutritional information per 100ml is energy 36kcal, protein 0. 2g, fat 0g, carbohydrates 8.7g, sodium Omg, sucrose l.Og.)
- BCAA tyrosine, methionine, ferrolanine, and glutamine in the amounts shown in Table 2 below. did.
- 3 kinds of branched chain amino acids were used for BCAA.
- Experiment group 1 was to drink 200 ml of beverage at one time.
- Experiment group 1 to 4 shown in Table 2 was conducted twice for each experiment, and experiment groups 5 and 6 were each conducted once for a total of 10 experiments.
- Experiment group 1 ⁇ Experiment group 2 ⁇ Experiment group 3 ⁇ Experiment group 4 ⁇ Experiment group 5 ⁇ Experiment group 1 ⁇ Experiment group 2 ⁇ Experiment group 3 ⁇ Experiment group 4 ⁇ Experiment group 6).
- the multifaceted emotional state scale test was performed by feeling about the multifaceted emotional state scale items for tabulating results shown in Table 3 (Terazaki Masaharu et al., The Japanese Journal of Psychology, 1992, Vol. 62.No. 6, 350-356). Yes: 3 points, I feel a little: 2 points, I don't feel so much 1 point: I don't feel it at all 0 points were given for each item. After that, the items No3, 11, 26, 3 6, 42, 48, 54, 64, 67, and 80 are included as fatigue items that are thought to be linked to brain fatigue (acute fatigue: sudden fatigue). The subjects' scores were calculated. The multifaceted emotional state scale test answers the evaluation at the time of answering, and the answer to the selected item evaluates acute fatigue. In the actual inspection, the items in Table 3 were rearranged from No. 1 to No. 87 in ascending order.
- POMS had a great deal of power (score 0) for the 65 evaluation items listed in the Japanese version of POMS (Kazuhito Yokoyama et al., Japanese version of POMS No.851, 2002, Kaneko Shobo). Scores were given on a scale of 4). Then, according to the evaluation described in the POMS, scores were obtained for F-items indicating “motivation” (decreased vitality) (tired, unwilling to do things, crammed, hesitant, tired, tired, unless tired). Unlike the multi-faceted emotional state scale test, POM S responds with an evaluation during the period up to 1 week before the test, and the response to the selected item evaluates chronic fatigue. Become.
- Tables 4 and 5 show the results of the multifaceted emotional state test, and Table 6 shows the POMS test. The test results are shown. The effective rate was expressed as the number of subjects whose score decreased compared to test group 1 (control group).
- Subject A-1 means the first experiment
- A-2 means the second experiment. The same applies to Subject B and later.
- composition for recovering or preventing fatigue according to the present invention exhibits effective suppression and improvement for brain fatigue exhibiting symptoms different from physical fatigue, and is capable of advocating a new effect. ! Offering functional foods and medicines.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/883,173 US20080114067A1 (en) | 2005-01-31 | 2005-01-31 | Composition for Recovery From or Prevention of Central Nervous System Fatigue |
PCT/JP2005/001357 WO2006080086A1 (ja) | 2005-01-31 | 2005-01-31 | 中枢神経系の疲労回復又は疲労予防のための組成物 |
JP2007500397A JP5604673B2 (ja) | 2005-01-31 | 2005-01-31 | 中枢神経系の疲労回復又は疲労予防のための組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2005/001357 WO2006080086A1 (ja) | 2005-01-31 | 2005-01-31 | 中枢神経系の疲労回復又は疲労予防のための組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006080086A1 true WO2006080086A1 (ja) | 2006-08-03 |
Family
ID=36740121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/001357 WO2006080086A1 (ja) | 2005-01-31 | 2005-01-31 | 中枢神経系の疲労回復又は疲労予防のための組成物 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20080114067A1 (ja) |
JP (1) | JP5604673B2 (ja) |
WO (1) | WO2006080086A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010150192A (ja) * | 2008-12-25 | 2010-07-08 | Uha Mikakuto Co Ltd | シスチン−アミノ酸複合体及びその製造方法 |
JPWO2010041647A1 (ja) * | 2008-10-06 | 2012-03-08 | 株式会社明治 | アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤 |
JP2019058140A (ja) * | 2017-09-27 | 2019-04-18 | 味の素株式会社 | 栄養組成物 |
US11045437B2 (en) | 2018-08-27 | 2021-06-29 | Ajinomoto Co., Inc. | Composition for improving brain function |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6578351B2 (ja) * | 2014-05-23 | 2019-09-18 | 協和発酵バイオ株式会社 | 集中力を向上するための方法および組成物 |
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
PE20200747A1 (es) | 2017-08-14 | 2020-07-24 | Axcella Health Inc | Composiciones de aminoacidos para el tratamiento de enfermedad hepatica |
MA52971A (fr) | 2018-06-20 | 2021-04-28 | Axcella Health Inc | Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60202814A (ja) * | 1983-11-30 | 1985-10-14 | ブ−リンガ− ビオケミ−ア ロビンソチエタ ペル アツィオーニ | 人間の第4期睡眠増強剤 |
JPH09249556A (ja) * | 1996-01-09 | 1997-09-22 | Rikagaku Kenkyusho | アミノ酸組成物 |
WO2002034257A1 (fr) * | 2000-10-27 | 2002-05-02 | Meiji Dairies Corporation | Agents de recuperation ou de prevention de la fatigue dans le systeme nerveux central et aliments de recuperation ou de prevention associes |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2947044B2 (ja) * | 1993-01-27 | 1999-09-13 | 味の素株式会社 | 免疫不全症候群治療の補助療法剤 |
EP0873754B1 (en) * | 1996-01-09 | 2003-07-30 | Riken | Amino acid compositions |
US6960358B2 (en) * | 2001-01-12 | 2005-11-01 | Crippen Raymond K | Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages |
EP1656454A4 (en) * | 2003-07-08 | 2011-06-22 | Novus Int Inc | PROCESS FOR METHIONINAL RECOVERY |
MX2007002209A (es) * | 2004-08-25 | 2007-11-08 | Multi Formulations Ltd | Composiciones y metodos para activar la sintesis de proteinas y para desactivar procesos de catabolicos dentro del musculo esqueletico. |
-
2005
- 2005-01-31 WO PCT/JP2005/001357 patent/WO2006080086A1/ja not_active Application Discontinuation
- 2005-01-31 JP JP2007500397A patent/JP5604673B2/ja active Active
- 2005-01-31 US US11/883,173 patent/US20080114067A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60202814A (ja) * | 1983-11-30 | 1985-10-14 | ブ−リンガ− ビオケミ−ア ロビンソチエタ ペル アツィオーニ | 人間の第4期睡眠増強剤 |
JPH09249556A (ja) * | 1996-01-09 | 1997-09-22 | Rikagaku Kenkyusho | アミノ酸組成物 |
WO2002034257A1 (fr) * | 2000-10-27 | 2002-05-02 | Meiji Dairies Corporation | Agents de recuperation ou de prevention de la fatigue dans le systeme nerveux central et aliments de recuperation ou de prevention associes |
Non-Patent Citations (5)
Title |
---|
ABE T.: "Aminosan Engine to VAAM", THE JOURNAL OF THERAPY, vol. 86, no. 4, 2004, pages 168 - 173, XP003000460 * |
ACWORTH I. ET AL.: "Effects of sustained exercise on concentrations of plasma aromatic and branched-chain amino acids and brain amines", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 137, no. 1, 1986, pages 149 - 153, XP003000464 * |
KISHI K.: "Physical Exercise and Protein and Amino Acid Requirements", REPORTS OF THE RESEARCH COMMITTEE OF ESSENTIAL AMINO ACIDS (JAPAN), no. 150, 1997, pages 19 - 25, XP003000461 * |
KOBAYASHI H.: "Sports to Aminosan Supplement", SHOKU NO KAGAKU, no. 255, 1999, pages 88 - 93, XP003000462 * |
OKUMURA K. ET AL.: "Exercise-induced changes in branched chain amino acid/aromatic amino acid atio in the rat brain and plasma", JAPANESE JOURNAL OF PHARMACOLOGY, vol. 45, no. 2M, 1987, pages 243 - 248, XP003000463 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2010041647A1 (ja) * | 2008-10-06 | 2012-03-08 | 株式会社明治 | アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤 |
JP2010150192A (ja) * | 2008-12-25 | 2010-07-08 | Uha Mikakuto Co Ltd | シスチン−アミノ酸複合体及びその製造方法 |
JP2019058140A (ja) * | 2017-09-27 | 2019-04-18 | 味の素株式会社 | 栄養組成物 |
US11045437B2 (en) | 2018-08-27 | 2021-06-29 | Ajinomoto Co., Inc. | Composition for improving brain function |
Also Published As
Publication number | Publication date |
---|---|
US20080114067A1 (en) | 2008-05-15 |
JPWO2006080086A1 (ja) | 2008-06-19 |
JP5604673B2 (ja) | 2014-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200347413A1 (en) | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy | |
CA2784836C (en) | Improved method of administering .beta.-hydroxy-.beta.-methylbutyrate (hmb) | |
Higgins et al. | Energy beverages: content and safety | |
WO2006080086A1 (ja) | 中枢神経系の疲労回復又は疲労予防のための組成物 | |
JP5714227B2 (ja) | アンドログラホリドを有効成分とする抗疲労剤及び経口組成物 | |
JP2014129394A (ja) | アミノ酸組成物を含有する疲労防止剤 | |
JPWO2002034257A1 (ja) | 中枢神経系の疲労回復又は予防剤及び疲労回復又は予防のための食品 | |
JPWO2004019928A1 (ja) | 肝疾患治療剤 | |
JP6166786B2 (ja) | 脳機能低下の予防または改善剤 | |
WO2012169600A1 (ja) | アミノ酸組成物 | |
JP2015520229A (ja) | 神経心理学的障害の治療用の組成物および方法 | |
JP4610499B2 (ja) | 食品組成物 | |
JP2006193435A (ja) | 疲労改善剤 | |
CN101610790B (zh) | 新颖的组合物及其用途 | |
US20230129451A1 (en) | Amino acid compositions and methods of manufacturing the compositions | |
Satyanand et al. | A study of beet root derived dietary nitrate efficacy on performance of Runners | |
JP2017070271A (ja) | 食品またはサプリメント。 | |
TW201808120A (zh) | 行動體力提升劑 | |
JP7460327B2 (ja) | 経口組成物 | |
JP6170166B2 (ja) | 脳機能低下の予防または改善剤 | |
Bryan et al. | The Role of Nitric Oxide Supplements and Foods in Cardiovascular Disease | |
JP2021011470A (ja) | 肉体疲労の回復又は予防剤 | |
US20130018061A1 (en) | Method for Improving Exercise and Recovery From Exercise | |
JP2009106253A (ja) | 運動持久力増強効果を有する機能性コーヒー | |
Barr | The NO2/Arginine Scam (deel I) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007500397 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11883173 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05709514 Country of ref document: EP Kind code of ref document: A1 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 5709514 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11883173 Country of ref document: US |